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LETTERS TO THE EDITOR 1213that additional factors are required. Our study also confirmed the
association of FLG mutations and early-onset infantile eczema,
which is in line with previous work.6
Our ability to interrogate the role of sensitization in the
relationship between FLG mutations and food allergy in a large
population-based, age-matched, challenge-proved food allergy
cohort is a major and novel strength of this work. There is some
potential participation bias among negative control subjects
(higher immediate family history of allergic diseases compared
with the general population); however, such a bias would be
more likely to create a false-negative than a false-positive
association.
In conclusion, FLG mutations do not increase the risk of
food allergy over and above that of food sensitization among
1-year-old infants. These results confirm the biological plausi-
bility that decreased skin barrier function increases the risk of
food sensitization in early life, but other as yet undetermined
factors are important in the conversion from food sensitization
to allergy.
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Egg-allergic patients can be safely vaccinated
against influenza
To the Editor:
As the influenza vaccine contains residual egg protein, its
administration to egg-allergic patients had always raised theoret-
ical concerns about anaphylaxis.1 We report our experience with
the vaccination of egg-allergic patients with a trivalent inactivated
seasonal influenza vaccine administered during 5 seasons (2007-
2011) and summarize the current published clinical experience
with these patients.
We conducted a prospective cohort study recruiting and
vaccinating egg-allergic patients in 2010-2011 and 2011-2012
in 5 Canadian hospitals (Montreal, Quebec City, Sherbrooke,
Edmonton, and Vancouver). Egg allergy was defined as a history
of at least 1 sign or symptom of allergy (cutaneous, ocular, respi-
ratory, gastrointestinal, or cardiovascular symptoms) occurring
within 60 minutes of egg ingestion, and the confirmation of per-
sistent sensitization to egg (within 6 months of vaccination)
shown by a skin prick test response to egg at least 3 mm larger
than that of the saline control within 10 to 15 minutes, or an
egg-specific IgE level of 0.35 kU/L or more (UniCAP, Pharma-
cia). In 2010-2011, we recruited all patients with allergy to egg,
whereas in 2011-2012, the recruitment focused on patients with
severe allergic reaction defined as the occurrence of anaphylaxis
or cardiorespiratory symptoms upon egg ingestion. In both years,
patients (or their parents/legal guardian if minor patients) had to
provide written consent for the collection of data on adverse
events occurring within 24 hours following vaccination. We
also performed a retrospective cohort study of all egg-allergic
patients referred for administration of seasonal influenza at the
Sainte-Justine Hospital in Montreal, during the 2007-2008,
2008-2009, and 2009-2010 vaccination seasons. The definition
of egg allergy and the threshold for skin prick test were the
same as previously described, but the method of detection of
TABLE I. Published studies with 25 or more egg-allergic patients vaccinated against influenza
Reference
No. of patients No. of doses
All
Severe
allergy All
Severe
allergy
Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP, et al. Safety of influenza vaccination
in allergic children. J Infect Dis 1977;136:S652-55.
28 1 28 1
James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, et al. Safe administration of influenza
vaccine to patients with egg allergy. J Pediatr 1998;133:624-8.
83 27 83 27
Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allerg Clin Immunol 2002;110:834-40. 28 NR 28
Dorsey MJ, Song L, Geha T, Timmons A, Oettgen H, Schneider L. Influenza vaccine in 55 patients with egg
allergy. J Allergy Clin Immunol 2005;115:S250.
37 NR 37
Hotte SL, Lejtenyi C, Primeau MN. A 6 years experience with influenza vaccination in egg allergic patients.
J Allergy Clin Immunol 2008;121:S239.
115 NR 173
Esposito S, Gasparini C, Martelli A, Zenga A, Tremolati E, Varin E, et al. Safe administration of an inactivated
virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008;26:4664-8.
44 11 44 11
Park AY, Pien GC, Stinson R, Brown-Whitehorn, Spergel JM. Administration of influenza vaccine to patients
with egg allergy. J Allergy Clin Immunol 2008;121:S240.
45 NR 45
Saltzman RW, Park AY, Pien GC, Stinson R, Spergel JM. Administration of influenza vaccine to pediatric
patients with egg allergy. J Allergy Clin Immunol 2009;123:S175.
349 NR 349
Thanik ES, Cox AL, Sampson HA. Administration of a low egg-containing influenza vaccine [Fluarix] in an
egg-allergic pediatric population. J Allergy Clin Immunol 2010;125:AB25.
214* NR 214
Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics
2010;125:e1024-30.
171 NR 171
Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al. Safe vaccination of patients with
egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010;126:317-23.
830 164 830 164
Greenhawt MJ, Chernin AS, Howe L, Li JT, Sanders G. The safety of the H1N1 influenza A vaccine in egg
allergic individuals. Ann Allergy Asthma Immunol 2010;105:387-93.
105 25 105 25
Leo SH, Dean J, Chan ES. Safety of H1N1 and seasonal influenza vaccines in egg allergic patients in British
Columbia. Allerg Asthma Clin Immunol 2010;6:P4.
81* NR 81
Pien GC, LeBenger KS, Carotenuto DR, Difilippi M, Scolpino D, Simmons JM, et al. Coordination of
multidisciplinary resources for vaccination of egg-allergic individuals during an H1N1 (novel) influenza
pandemic. Allergy Asthma Proc 2010;31:507-10.
62 NR 62
Siret-Alatrista A, Bouali F, Demoly M, Bousquet PJ, Demoly P. The 2009-2010 H1N1 vaccination campaign
for patients with egg allergy in a region of France. Allergy 2011;66:298-9.
53 NR 53
Boden SR, LaBelle VS, Sedlak DA, Kim EH, Vickery BP, Burks AW. Safe administration of flu vaccine in
egg-allergic patients. J Allergy Clin Immunol 2011;127:AB114.
101 NR 206
Paschall VL, Siles RI, Bhatti H, Nolder PJ, Melton AL. Do egg-specific IgE levels predict reactions to
seasonal influenza or H1N1 vaccination? J Allergy Clin Immunol 2011;127:AB182.
62 NR 131
Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with
egg allergy. J Allergy Clin Immunol 2011;127:264-5.
64 NR 96
Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to
children with egg allergy of all severities. Ann Allergy Asthma Immunol 2011;106:446-7.
204 27 204 27
Webb L, Petersen M, Boden S, LaBelle V, Bird JA, Howell D, et al. Single-dose influenza vaccination of
patients with egg allergy in a multicenter study. J Allergy Clin Immunol 2011;128:218-9.
152 34 292 34
Pitt T, Kalicinsky C, Warrington R, Cisneros N. Assessment of epicutaneous testing of a monovalent
influenza A (H1N1) 2009 vaccine in egg allergic patients. Allergy Asthma Clin Immunol 2011;7:3.
59 NR 59
Schuler JE, King WJ, Dayneka NL, Rastelli L, Marquis E, Chad Z, et al. Administration of the adjuvanted
pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.
Can J Pub Health 2011;102:196-9.
62 NR 62
Forsdahl BA. Reactions of Norwegian children with severe egg allergy to an egg-containing influenza
A (H1N1) vaccine: a retrospective audit. BMJ Open 2012;2:e000186.
80 19 80 19
Fung I, Spergel JM. Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis.
J Allergy Clin Immunol 2012;129:1157-9.
56 56 119 119
Khan FS, Virant FS, Furukawa CT, Altman LC, Williams PV, Kennedy MS, et al. Influenza vaccine
administration in egg allergic children. J Allerg Clin Immunol 2012;129:AB70.
643 NR 643
Wainwaring Upton JE, Hummel DB, Kasprzak A, Atkinson AR. No systemic reactions to influenza vaccination in
egg-sensitized tertiary care pediatric patients. Allerg Asthma Clin Immunol 2012;8:2.
77 17 77 17
Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S, et al. Egg-allergic patients can be
safely vaccinated against influenza. J Allergy Clin Immunol 2012 (current study).
367 132 457 153
Totals 4172 513 4729 597
NR, Not reported.
*Number of doses, as number of patients not reported.
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Muenchen, Germany).
For both cohorts, patients were examined immediately before
vaccination, remained under observation for 60 minutes post-
vaccination, and were then reexamined for any sign of allergic
reaction. The vaccine used during all 5 seasons was the
split-virion trivalent inactivated influenza vaccine Fluviral
manufactured by GSK (Quebec City, Quebec, Canada). The
ovalbumin content for the lots used was provided by the
manufacturer: 0.09 mg/mL in 2007-2008, 0.03 mg/mL in 2008-
2009, 0.31 mg/mL in 2009-2010, up to 0.2 mg/mL in 2010-2011,
and up to 0.06 mg/mL for 2011-2012. The primary outcome was
the occurrence of anaphylaxis according to the Brighton Col-
laboration definition.2 The study was approved by the ethics
boards of all participating hospitals.
Over 5 influenza seasons, 457 doses of trivalent inactivated
seasonal influenza vaccines were administered to 367 patients
among whom 132 (153 doses) had a history of severe allergy to
egg (see Table E1 in this article’s Online Repository at www.
jacionline.org). Four patients reported mild allergic-like symp-
toms after previous influenza vaccination (1 urticaria, 2 vomiting,
and 1 eczema), but none experienced an adverse event when
given the current vaccine.While 13 patients developed mild aller-
gic-like symptoms in the 24 hours following vaccination, none of
the 367 patients developed anaphylaxis.
We then did a literature review and retrieved articles in English
or French in which at least 25 egg-allergic patients had been
vaccinated. PubMed was searched with the following MESH:
(influenza AND (vaccination or vaccine)) AND (egg AND
(allergy OR allergic)). Further studies or conference abstracts
were identified by citations in retrieved articles and by consulta-
tion with experts. Among the 87 articles retrieved from PubMed,
16 were studies including the vaccination of 25 or more egg-
allergic patients.We additionally found 10 conference abstracts of
studies with the sameminimal number of patients. Together, these
26 studies and the current study have enrolled 4172 patients
including 513 who were identified as patients with a history of
severe reactions (Table I). These patients received a total of 4729
doses, and none developed anaphylaxis.With no anaphylaxis after
4729 doses of vaccine, the 95% Clopper-Pearson exact CI of the
risk of anaphylaxis ranges from 0% to 0.08% (or 0 to 1 of 1250
doses).3 For the 597 doses administered to the 513 patients with
a history of severe allergic reaction to egg, the exact 95% CI of
the risk of anaphylaxis ranges from 0% to 0.62% (or 0 to 1 of
161 doses). Their risk of anaphylaxis is in fact smaller as many
studies in Table I had patients with severe allergy but simply did
not report the information regarding their number.
The clinical experience with influenza vaccination in egg-
allergic patients in our cohorts and in other studies displayed in
Table I has limitations. The amount of ovalbumin varied in the
different influenza vaccines used and was sometimes unknown
or low. Patients rarely had a recent positive food challenge con-
firming the persistence of egg allergy. Some studies included
young children with atopic conditions (eg, atopic dermatitis)
who had never eaten eggs but had a positive skin test result
and high levels of egg-specific IgE. These sensitized patients
are typically managed with recommendations of food avoidance
as if they were allergic, although the diagnosis of allergy for
these patients may be inaccurate. Despite these limitations, the
patients in Table I are representative of patients managed as
egg-allergic and the large number vaccinated with no ensuinganaphylaxis constitutes a strong scientific basis for new
recommendations.
Egg allergy is the second most frequent food allergy and
affects 1% to 2% of young children.4 While most patients will
eventually develop tolerance to eggs, it will still be present in
more than 60% by 6 years of age.5 In the United States, this
grossly corresponds to 150,000 to 250,000 influenza vaccine–el-
igible preschoolers. Many of these patients have not benefited
from the influenza vaccine in the past because of the fear of an-
aphylaxis or the difficulty of accessing an allergist as is often
recommended.1 Paradoxically, given their young age and the
high rate of concurrent asthma, these patients have a higher
risk of complications from influenza and are among those
most likely to benefit from this vaccine.6 The evidence gathered
over the past 15 years is overwhelmingly reassuring that this
risk is minimal. The published number of egg-allergic patients
safely vaccinated against influenza is nearly 4 times as large
as the number that ended the precautions regarding measles,
mumps and rubella (MMR) vaccine (4172 vs 1227).7 There
will always be a very small risk of anaphylaxis associated
with influenza or any other vaccination, but there is now robust
evidence that egg-allergic patients, even those with severe al-
lergy, can be safely vaccinated against influenza. The risk of an-
aphylaxis appears sufficiently low for patients with egg allergy
to be vaccinated like all other individuals, without requiring ad-
ministration by an allergist.
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Obesity is not a risk factor for repeat epineph-
rine use in the treatment of anaphylaxis
To the Editor:
Epinephrine is widely accepted as the first-line treatment for all
forms of anaphylaxis.1,2 Approximately 10% to 20% of the pa-
tients treated with epinephrine for anaphylaxis receive a second
dose,3-6 but the risk factors associated with repeat epinephrine
use remain poorly defined. Previous studies have suggested that
epinephrine administration with autoinjectors may be influenced
by a patient’s body habitus.7 Therefore, we sought to determine
whether obesity increases the risk for requiring 21 epinephrine
doses among patients who present to the emergency department
(ED) with anaphylaxis due to food allergy or stinging insect
hypersensitivity.
We performed a chart review at 4 New England teaching
hospitals: Brigham and Women’s Hospital (January 1, 2001, to
December 31, 2006), Children’s Hospital Boston (January 1,
2001, to December 31, 2006), Hasbro Children’s Hospital (Jan-
uary 1, 2004, to December 31, 2009), and Massachusetts General
Hospital (January 1, 2001, to December 31, 2006). We identified
all patients presenting to the ED for food allergy or stinging insect
hypersensitivity by using relevant International Classification of
Diseases, Clinical Modification Codes, Ninth Revision,8 includ-
ing 558.3 (allergic gastroenteritis), 693.1 (dermatitis due to
food), 708.0 to 708.9 (urticaria), 989.5 (toxic effect due to
venom), 995.0 (other anaphylactic shock), 995.1 (angioneurotic
edema), 995.3 (allergy, unspecified), 995.60 (anaphylactic shock
due to unspecified food), 995.61 to 995.69 (anaphylactic shock
due to a specified food), and 995.7 (other adverse food reactions,
not elsewhere classified). Cases were confirmed by allergist re-
view. We focused on the total number of epinephrine treatments
given during an anaphylaxis episode (including before and during
the ED visit) and the patient’s anthropomorphic data. Weight and
height measurements documented at the ED visit were preferen-
tially used. If measurements had been taken more than 3 months
from the ED visit, height/weight at the time of the ED visit was
estimated by using Centers for Disease Control and Prevention
growth charts in children (<18 years) and estimates of average
weight gain in US adults. Calculated body mass indexes wereclassified according to Centers for Disease Control and Preven-
tion growth indicators as underweight, healthy, overweight, or
obese. Medians with interquartile ranges were presented for con-
tinuous variables that were not normally distributed. Compari-
sons between groups were evaluated by using Kruskal-Wallis
rank sum tests for continuous variables and the x2 test or the
Fisher exact test for categorical variables, as appropriate. Multi-
variable models were performed using logistic regression. A 2-
sided P value of less than .05 was considered statistically
significant.
The study population comprised 321 ED patients (261 children
and 60 adults) who received epinephrine for anaphylaxis and had
data for both height and weight; 267 (83%) received 1 dose of
epinephrine, while 54 (17%) received 21 doses. There was no
difference in the need for additional doses of epinephrine between
children and adults (P5 .94) and no difference among the 4 insti-
tutions (P 5 .60). Demographic data, reaction history, and ED
treatments are summarized in Table I. Patients had a median age
of 8.5 (intraquartile range 3.0-16.4) years, and 47% were males.
When comparing patients who received 1 and 21 doses of epi-
nephrine, there was no difference in the inciting allergen, organ
system involvement, or timing/dosing of epinephrine.While those
receiving 21 doses of epinephrine were more likely to receive
b-agonists, there was no significant difference in other adjunctive
medications, including corticosteroids (85% vs 79%; P 5 .38).
Overall, 27 (8%) patients were underweight, 168 (52%) healthy
weight, 57 (18%) overweight, and 69 (22%) obese. The distribu-
tion of body mass index categories was similar in those receiving
1 versus 21 doses (P 5 .83). There was no difference when sep-
arately examining these distributions among children (P 5 .92)
and adults (P 5 .81). There was also no significant association
when comparing categories of underweight/healthy versus over-
weight/obese (data not shown). Finally, when adjusting for age
and sex, there remained no significant association between
obesity (vs nonobesity) and receiving 21 doses (odds ratio
1.22; 95% CI 0.77-1.93; P 5 .40).
Anaphylaxis is a potentially life-threatening medical emer-
gency that is frequently incited by exposure to foods or stinging
insects.1 The primary treatment for anaphylaxis is the prompt ad-
ministration of epinephrine. Current practice guidelines recom-
mend that all patients at risk for anaphylaxis receive a
prescription for an epinephrine autoinjector and education on
its proper use.1,2 Furthermore, on the basis of recently published
data that 10% to 20% of the patients require repeat dosing,3-6 ex-
perts now recommend that patients at risk for anaphylaxis always
carry 2 doses.2 Our current analysis—based on a partially over-
lapping population of ED patients who were included in our pre-
vious studies5,6—is consistent with the reported percentages of
anaphylaxis patients who require repeat doses of epinephrine.
Repeat dosing could be a result of biphasic reactions or
inadequate treatment response. In prior work,5 we reported that
most patients received the second dose within 1 hour of the first
dose, suggesting that inadequate treatment response was the
more likely explanation. Lack of response to epinephrine could
be a result of failure to administer it in a timely manner or a rapid
progression of the anaphylactic event. Other studies have sup-
ported that older age and asthmamay be associatedwith additional
treatments, which may be a reflection of increased reaction sever-
ity.4,6 In the current study, all patients had reactions that met crite-
ria for anaphylaxis and organ system involvement was similar
among patients who received 1 versus 21 doses of epinephrine.
TABLE E1. Characteristics of egg-allergic patients vaccinated against seasonal influenza between 2007 and 2011
n (%)
All patients Patients with severe allergy
Retrospective Prospective Total (N 5 367) Retrospective Prospective Total (N 5 132)
2007-2008 to
2009-2010
(n 5 137)
2010-2011
(n 5 187)
2011-2012
(n 5 43)
2007-2008 to
2009-2010
(n 5 31)
2010-2011
(n 5 58)
2011-2012
(n 5 43)
Sex
Male 87 (63) 98 (52) 28 (65) 213 (58) 23 (74) 29 (50) 28 (65) 80 (61)
Age (y)
<2 29 (21) 21 (11) 6 (14) 56 (15) 5 (16) 4 (7) 6 (14) 15 (11)
2-4 53 (39) 72 (39) 11 (26) 136 (37) 14 (45) 16 (28) 11 (26) 41 (31)
5-11 51 (37) 64 (34) 18 (42) 133 (36) 11 (36) 22 (38) 18 (42) 51 (39)
>12 4 (3) 30 (16) 7 (16) 41 (11) 1 (3) 16 (28) 7 (16) 24 (18)
Skin prick test to egg
>_3 mm 137 (100) 181 (97) 39 (91) 357 (97) 31 (100) 55 (95) 39 (91) 125 (95)
>_10 mm 71 (52) 72 (39) 14 (33) 157 (43) 22 (71) 22 (38) 14 (33) 58 (44)
Egg IgE (kUA/L)*
<0.35 1 (1) 14 (7) 2 (5) 17 (5) 0 7 (12) 2 (5) 9 (7)
0.35-<2 22 (18) 20 (11) 2 (5) 44 (12) 2 (9) 8 (14) 2 (5) 12 (9)
2-<7 27 (22) 27 (14) 7 (16) 61 (17) 8 (36) 6 (10) 7 (16) 21 (16)
7-17 31 (25) 15 (8) 1 (2) 47 (13) 5 (23) 4 (7) 1 (2) 10 (8)
17.5-99 43 (35) 18 (10) 7 (16) 58 (16) 7 (32) 7 (12) 7 (16) 16 (16)
Tolerate baked goods 49 (36) 53 (28) 12 (28) 114 (31) 6 (19) 18 (31) 12 (28) 36 (27)
Naive to flu vaccine 84 (61) 81 (43) 11 (26) 176 (48) 17 (55) 28 (48) 11 (26) 56 (42)
Vaccinated
Single dose 227 (100) 170 (91) 41 (95) 438 (96) 52 (100) 45 (78) 41 (95) 138 (91)
2 doses (10% 1 90%) 0 17 (9) 2 (5) 19 (4) 0 13 (22) 2 (5) 15 (9)
Allergic symptoms <_24 h
following influenza
vaccination (all were mild)
0 9 (5) 4 (9) 13 (6) 0 2 (3) 4 (9) 6 (6)
Significant differences with P values <.05 between severe and nonsevere egg-allergic patients are indicated in bold characters.
*Measured with UniCAP for 2010-2011 and 2011-2012 and with Immulite for 2007-2010.
There were 114 patients (including 36 severe cases) who had challenge with a baked good and tolerated it well. While the tolerance to baked goods in patients with severe allergy
may suggest milder severity, this does not rule out the risk of severe reaction to uncooked egg proteins.
Some patients had more than 1 dose over several seasons. Percentage calculated on the total number of doses administered.
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